WO2023237902 - TREATMENT OF DRY EYE DISEASE USING MITOCHONDRIALLY TARGETED ANTIOXIDANTS
National phase entry:
Publication Number
WO/2023/237902
Publication Date
14.12.2023
International Application No.
PCT/IB2022/000316
International Filing Date
06.06.2022
Title **
[English]
TREATMENT OF DRY EYE DISEASE USING MITOCHONDRIALLY TARGETED ANTIOXIDANTS
[French]
TRAITEMENT DU SYNDROME DE L'ŒIL SEC À L'AIDE D'ANTIOXYDANTS CIBLANT LES MITOCHONDRIES
Applicants **
MITOTECH S.A.
Inventors
SKULACHEV, Maxim
PETROV, Anton
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2504 | |
| EPO | Filing, Examination, Granting | 17423 | |
| Japan | Filing, Examination, Granting | 2741 | |
| South Korea | Filing, Examination, Granting | 2993 | |
| USA | Filing, Examination, Granting | 7340 |
Total:
33,001
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Formulations and methods of using mitochondrially targeted antioxidants (SkQ) to improve dry eye conditions in subjects having a tear production of ≥ 7 mm measured by a Schirmer's test are provided. The methods provide benefits to the population-specific group of subjects but do not provide benefits to subjects having a tear production of < 7 mm, as measured by a Schirmer's test.[French]
L'invention concerne des formulations et des procédés d'utilisation d'antioxydants ciblant les mitochondries (SkQ) pour améliorer les états de sécheresse oculaire chez des sujets ayant une production de larmes ≥ 7 mm mesurée par un test de Schirmer. Les procédés fournissent des avantages au groupe spécifique de population de sujets mais ne fournissent pas d'avantages à des sujets ayant une production de larmes < 7 mm, telle que mesurée par un test de Schirmer.